Other substances

D12 (IgG)

An anti-RBD (SARS-CoV-2) neutralizing antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

D12 (IgG) is a human SARS-CoV-2-neutralizing antibody. It was created by reformatting a synthetic Fab which was selected for its affinity for SARS-CoV-2 Spike protein RBD using phage display into an IgG (Kim et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library
Spike protein Biophysical assay In vitro Antibody 		in vitro binding assay; in vitro biophysical assay; HEK-293T cells expressing ACE2; Vero cells; SARS-CoV-2 Spike (D614G) pseudovirus; SARS-CoV-2 live virus (NCCP43326) 4.56

The antibody bound SARS-CoV-2 Spike RBD and neutralized SARS-CoV-2 pseudovirus and live virus with IC50s of 0.035 μg/mL and 0.036 μg/mL, respectively, in vitro.

 Feb/15/2021
Export (.csv)